US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ホーム
投資
株式
イタリア
BIT
REVO Insurance (REVO) 銘柄情報

REVO Insurance (REVO)

25.40

-0.35

(-1.36%)

終了 6月21日 12:30AM

REVO Insurance (REVO) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

25.40

( -1.36% )

買値

25.10

売値

26.10

出来高

20,654

25.25 日の範囲 25.75

14.96 52 週間の範囲 26.50

時価総額

前日終値

25.75

始値

25.45

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

69,369 €

発行済株式数

28,736,830

配当利回り

(1.00%)

PER

30.64

1 株当たり利益 (EPS)

0.85

歳入

415.23M

純利益

22.41M

REVO Insurance S.p.A. operates as an insurance company in Italy. The company offers non-life insurance with a focus on specialty lines and parametric risks business, with a focus on the SME sector. It also provides insurance against parametric, deposits, financial lines, property and engineering, ca... REVO Insurance S.p.A. operates as an insurance company in Italy. The company offers non-life insurance with a focus on specialty lines and parametric risks business, with a focus on the SME sector. It also provides insurance against parametric, deposits, financial lines, property and engineering, casualty, agriculture, surety, aviation, private credit, fine art, marine, and legal protection. The company is headquartered in Milan, Italy. 詳細を表示

セクター

Finance

業界

Insurance

ウェブサイト

www.revoinsurance.com

本社

Milan, Italy

設立

-

REVO Insurance is listed in the Finance sector of the イタリア証券取引所 with ticker REVO. The last closing price for REVO Insurance was 25.75 €. Over the last year, REVO Insurance shares have traded in a share price range of 14.96 € to 26.50 €.

REVO Insurance currently has 28,736,830 shares in issue. The market capitalisation of REVO Insurance is 729.92 € million. REVO Insurance has a price to earnings ratio (PE ratio) of 30.64.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.2	0.793650793651	25.2	26.5	24.95	52317	25.96656785	DE
4	2.8	12.389380531	22.6	26.5	21.55	45302	24.10065764	DE
12	2.9	12.8888888889	22.5	26.5	21.55	60957	24.0621444	DE
26	7.3	40.3314917127	18.1	26.5	18.1	82972	23.7667568	DE
52	10.08	65.7963446475	15.32	26.5	14.96	54493	21.80584867	DE
156	16.56	187.330316742	8.84	26.5	7.86	36192	16.56620924	DE
260	15.34	152.485089463	10.06	26.5	7.78	26383	15.32754577	DE

REVO - Frequently Asked Questions (FAQ)

What is the current REVO Insurance share price?

The current share price of REVO Insurance is 25.40 €

How many REVO Insurance shares are in issue?

REVO Insurance has 28,736,830 shares in issue

What is the market cap of REVO Insurance?

The market capitalisation of REVO Insurance is EUR 729.92M

What is the 1 year trading range for REVO Insurance share price?

REVO Insurance has traded in the range of 14.96 € to 26.50 € during the past year

What is the PE ratio of REVO Insurance?

The price to earnings ratio of REVO Insurance is 30.64

What is the cash to sales ratio of REVO Insurance?

The cash to sales ratio of REVO Insurance is 1.81

What is the registered address of REVO Insurance?

The registered address for REVO Insurance is Via Monte Rosa 91, Milan, Milan, 20149

What is the REVO Insurance website address?

The website address for REVO Insurance is www.revoinsurance.com

Which industry sector does REVO Insurance operate in?

REVO Insurance operates in the Insurance sector

100lbStriper

100lbStriper 3分前

Stokd $NLST #2 Think of it as 4 angles / parts to Netlist litigation:

1) ITC — 2 actions (1 investigation instituted / 1 new complaint pending).

2) Appeals — 3 District Court TX cases on completed trials/wins & PTAB decisions on the patents involved currently at CAF

100lbStriper

100lbStriper 4分前

Stokd $NLST #1 I'll update the litigation chart with new ITC & District Court action, but essentially:

Netlist's focus (aside Micron) is on ITC, with Dist Crt infringement cases on patents litigated at ITC as back up should the need to litigate continue if ITC does not award injunct

brazen22

brazen22 4分前

The right answer may be the simplest one.

If this is minutia, then the minutia is that MHRA has not approved because the MAA has not yet satisfied MHRA.

Not BP. Not skeptics. Not market makers. Not message board posters. Not me. Not conferences. Not expanded labels.

100lbStriper

100lbStriper 7分前

Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest https://www.federalregister.gov/documents/2026/06/22/2026-12369/notice-of-receipt-of-complaint-solicitation-of-comments-relating-to-the-public-interest

EZ2

97-54-71-45. 🙏

tkg

Truly an absolute standout individual to have on board as a Director...now with a quantum angle added to the mix!

Ciesla is an accomplished innovator and product development leader with a proven track record and is an inventor of more than 100 patents and patent applications. He most

tkg

IQM Quantum Computers (founded in 2018, headquartered in Finland) is a global leader in building full-stack, on-premises superconducting quantum computers. They design their own processor chips and provide systems for research labs, high-performance computing centers (HPC), and enterprises worldwide

tkg

Dr. Craig Ciesla joining IQM Quantum Computers as Chief Technology Officer (CTO) is a notable positive driver for Lightwave Logic, Inc. (NASDAQ: LWLG). As an independent director on the Lightwave Logic Board of Directors, his elevated visibility and influence in the quantum computing ecosystem offer

joe_techi

joe_techi 1時間前

Wall Of Voodoo - Me And My Dad
https://www.youtube.com/watch?v=lWvPoamMIwQ

Investor2014

Investor2014 1時間前

Many of the core criticisms are directionally supported by later events and primary documents, but the report also uses inflammatory language, overstates some legal conclusions, conflates Alzheimer's and Rett syndrome at points, and treats negative interpretations as established facts.

Investor082

Investor082 2時間前

Gary,

This is a nice post to go into the record books, LOL! We will check in every quarter to measure progress.

The only problem is you, Flipper, and other minions predicted $23+ share price back in 2022. 4 years later, the two of you and other minions have missed by

Investor082

Investor082 2時間前

While the shareholders got decimated and will continue to get destroyed going forward, LOL! ;)

Any update on the 10 year survival data for NICE?

eagle8

eagle8 2時間前

Doc logic,

we have already seen and read many discussions about the costs NICE is willing/able to pay for DCvax.
If you look at the NEW costs for NICE after approval for DCvax, surely you can state:
Chemo expenses are being minimized and DCvax is being introduced.

Tdl9586

Tdl9586 2時間前

are you going to vote ? and how are you going to vote ?

Seminole Red

Seminole Red 2時間前

theres alot of big names on the board, I dont think its going to matter unless Clark Chokes and 2 or 3 others step up.....as Fitz should say, 'Dont fall down like me....

Kam8

Kam8 2時間前

HI Skitahoe

The most important thing is LP prepared 900M share suddenly.

I am praying BP would pay $8+ for those 900shares.

Or MRK acquire nwbo with $30 Billion suddenly. (Merger)

rocketeer357

rocketeer357 2時間前

That rent on Freddy is way too high. And the roles are reversed. We're the team that guts farm systems by trading players in their walk year. You're one of the teams that trades the farm for the walk year guys. We can't afford to pay players 20 million plus per year if they don't play. You can and d

fuagf

fuagf 2時間前

He being a decent wind player as we read, he just had a bad day, is all.

Seminole Red

Seminole Red 2時間前

Henly is a top fairway hitter too and strings pars forever, usually .... theres no trees on this course to block the wind

fuagf

fuagf 2時間前

Yep. On Henley though, as thought could be;

Russell Henley is widely regarded as one of the best wind and adverse-condition players on the PGA Tour.

https://www.google.com/search?q=pga+stats+-+how+is+henley+in+the+wind+&client=firefox-b-d&hs=rwRV&sca_esv=77e9a8666bf485

Seminole Red

Seminole Red 3時間前

I guess if you look back on history the US Open has always been a tough venue wherever its played

DocLee

DocLee 3時間前

Hi, Dedugan. I share the frustration that you and many (?most?) others feel at the extended wait that we are all are experiencing for the MAA to be approved.

However, I don't think that your concern - "why can't MHRA approve it for use at the patient's and physician's discretion and

Wayne R

Wayne R 3時間前

Yup, the new reality isn't buying or selling based on fundamentals, it's, baah, why not. Follow the sheep 🐑

sony12

sony12 3時間前

Is Klug in jail ?

DoF

Or maybe to spend more time on his other pusuits, like
Digialage Inc (Peter Michaels, President)
SocialSafe Inc (Peter Michaels, President and Director, Neal Newgard & Awan D Nord, Directors)
ThaHOUSE Inc (Ian Caloun, President, Peter Michaels, Director)

Ubs Ag London Branch Aut...

DJ US Nonlife Insurance ...

Lleidanetworks Serveis T...

First Trust Large Cap Gr...

Cannabis Bioscience (ID)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。